Effect of Electroacupuncture on Treating the First-episode Depression
NCT05818735 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 204
Last updated 2023-12-15
Summary
Depression is a disease that endangers the physical and mental health of all human beings. Only 30-40% of patients with initial episode depression are cured after treatment with antidepressants. Acupuncture is a widely recognized therapy to treat depression in clinical practice, and it can effectively relieve the depressive mood and improve related physical symtoms in patients with mild to moderate depression. This randomised controlled trial (RCT) is aimed to investigate the efficacy and safety of electroacupuncture (EA) in the treatment for patients with the first-episode of mild to moderate depression.
Conditions
Interventions
- OTHER
-
electroacupuncture (EA) treatment
The regular acupuncture treatment will be applied at the acupoints including Baihui (GV20), Yintang (GV29), Guanyuan (RN4), Qihai (RN6), bilateral ZuSanli (ST36) and bilateral SanYinjiao (SP6). After needle insertion, rotating or lifting-thrusting manipulation will be applied for 'De qi' sensation. Three pairs of electrodes of the electroacupuncture apparatus will be connected to the needles of GV20 and GV29, and bilateral ST36 and SP6 for 25 minutes, delivering a continuous wave with a frequency of 2-8Hz which is based on the tolerance of each patient. The selection of matching acupuncture points will be determined by the acupuncturist according to the patients' different syndrome patterns.
- OTHER
-
sham acupuncture (SA) treatment
The sham acpunture treatment will be applied at the same acupoints as the EA treatment with the Streitberger placebo needles. When the blunt needle tip of the placebo needles touches the skin, the patient will get a pricking sensation, but there is no real needle inserted into the skin. The electroacupuncture apparatus will be set on the table beside the patients and two pairs of electrodes will be connected to the needles at bilateral ST36 and SP6. Acupuncturists will turn on the apparatus but all indicators will be set to '0'. Participants will be informed when needles are removed after 25 minutes. Acupuncturists will use dry cotton balls to press the skin around the acupoints when withdrawing the needles so that patients can feel the withdrawal of the 'needles'.
- DRUG
-
Escitalopram 10mg
Escitalopram will be used as the antidepressants for relieving patients' depressive mood. The dose of the drug will be the minimum clinical starting dose of 10 mg once daily, taken orally in the morning, for a period of 3 months. During the intervention period, patients will be allowed to increase the drug dose (up to 20 mg) according to their mental status. Patients will record the details of the drug dose, duration of dosing,responses and possible side effects on a drug dairy. Pateints will receive 7 tablets of escitalopram from an independent dispencer at a set time each week. They may receive additional dose of escitalopram once again during the week if necessary and it will be recorded by the dispenser.
- DRUG
-
Placebo drugs are tablets of the same color and size as escitalopram tablets, consisting mainly of starch, and will be tested for safety before being used in the trial. The way the medication is dispensed, the details of how the medication is administered, the dosage, and the record of the drug diary are consistent with the application of the real drugs.
Sponsors & Collaborators
-
Shanghai Mental Health Center
collaborator OTHER -
Xuhui Central Hospital, Shanghai
collaborator OTHER -
Shanghai Huangpu District Mental Health Center
collaborator UNKNOWN -
Shanghai Municipal Hospital of Traditional Chinese Medicine
lead OTHER
Principal Investigators
-
Shifen Xu, Doctor · Shanghai Municipal Hospital of Traditioal Chinese Medicine
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-12-01
- Primary Completion
- 2025-12-31
- Completion
- 2026-05-01
Countries
- China
Study Locations
More Related Trials
-
Comparison of Anodal Transcranial Direct Current Stimulation (t-DCS) and Sham Stimulation in Patients With Treatment-resistant Depression
NCT02141776 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of HD-tDCS Assisted ECT for Depression Disorder
NCT06109480 ·Status: RECRUITING ·Phase: NA
-
Electroencephalography-based Precise Repetitive Transcranial Magnetic Stimulation Treatment
NCT06385405 ·Status: RECRUITING ·Phase: NA
-
Transcranial Alternating Current Stimulation for Treatment-Resistant Depression
NCT06172413 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Intervention Effect of High Definition Transcranial Alternating Current Stimulation (HD-tACS) on Depressive Disorder
NCT05932706 ·Status: COMPLETED ·Phase: NA
-
The Study About Mechanism of Transcranial Magnetic Stimulation Treatment of Depression Using Medical Imaging
NCT03500029 ·Status: UNKNOWN ·Phase: PHASE1
-
Low Dose Intravenous Ketamine in Treatment Resistant Depression Patients
NCT02935595 ·Status: COMPLETED ·Phase: PHASE2
-
The Efficacy of Cranial Electrostimulating Therapy for Depression and Anxiety Among Homeless Adults
NCT02732561 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety of tACS for Depression: a Multicenter RCT Study
NCT06891326 ·Status: RECRUITING ·Phase: NA
-
Multimodal Biomarkers of Electroconvulsive Therapy in Severe and Treatment-resistant Depression
NCT05463562 ·Status: RECRUITING
-
Portable Transcranial Electrical Stimulation and Internet-Based Behavioral Therapy for Major Depression Study
NCT04889976 ·Status: COMPLETED ·Phase: NA
-
Transcranial Direct Current Stimulation for Depression
NCT07042217 ·Status: RECRUITING ·Phase: NA
-
Transcranial Direct Current Stimulation as Home Treatment in Depression
NCT05123872 ·Status: COMPLETED ·Phase: NA
-
Intervention Effect of High Definition Transcranial Direct Current Stimulation (HD-tDCS) on Depressive Disorder
NCT05286645 ·Status: COMPLETED ·Phase: NA
-
A Clinical Trial of Magnetic Stimulation in Depression
NCT00711568 ·Status: COMPLETED ·Phase: PHASE2
-
Needle-embedding Therapy Alleviates Depressive Symptoms and Resets the Function of Executive Control System in Subthreshold Depression People
NCT04319562 ·Status: UNKNOWN ·Phase: NA
-
the Safety and Effectiveness of Precise rTMS Based on Neuroimaging in the Treatment of Adolescent Depression With Anhedoniadepression With Anhedonia
NCT05544071 ·Status: RECRUITING ·Phase: NA
-
Non-invasive Brain Stimulation Normalizes Dopaminergic Transmission in the Frontostriatal Circuit to Alleviate Depression With Metabolic Disorders.
NCT05117983 ·Status: UNKNOWN ·Phase: NA
-
Efficacy and Safety of Task-specific, Biomarker-driven, HD-ctACS inTRD.
NCT07184697 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Neuromodulation in Depressed and Schizophrenic Patients - Changing MEP (Muscle Evoked Potentials) by tDCS (Transcranial Direct Current Stimulation)
NCT01150734 ·Status: COMPLETED
-
Neural Mechanisms of Temporal Interference Stimulation on Improving Social Reward Function in Depression
NCT07287878 ·Status: RECRUITING ·Phase: NA
-
The Therapeutic Effect of Transcranial Direct Current Stimulation on Depression in Parkinson's Disease
NCT02917122 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Personalized High-Definition Transcranial Direct Current Stimulation (HD-tDCS) Treatment for Major Depressive Episode
NCT05498441 ·Status: UNKNOWN ·Phase: NA
-
HD-tDCS for Adolescent Bipolar Depression Targeting S1
NCT07246044 ·Status: RECRUITING ·Phase: NA
-
Home-Based Transcranial Direct Current Stimulation (tDCS) for Depression in Multiple Sclerosis (MS)
NCT06901687 ·Status: RECRUITING ·Phase: PHASE2